454 related articles for article (PubMed ID: 12767066)
41. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
42. VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells.
Karumanchi SA; Jiang L; Knebelmann B; Stuart-Tilley AK; Alper SL; Sukhatme VP
Physiol Genomics; 2001 Apr; 5(3):119-28. PubMed ID: 11285365
[TBL] [Abstract][Full Text] [Related]
43. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
44. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
45. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
Lemm I; Lingott A; Pogge v Strandmann E; Zoidl C; Bulman MP; Hattersley AT; Schulz WA; Ebert T; Ryffel GU
Mol Carcinog; 1999 Apr; 24(4):305-14. PubMed ID: 10326868
[TBL] [Abstract][Full Text] [Related]
46. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
47. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth.
Baba M; Hirai S; Kawakami S; Kishida T; Sakai N; Kaneko S; Yao M; Shuin T; Kubota Y; Hosaka M; Ohno S
Oncogene; 2001 May; 20(22):2727-36. PubMed ID: 11420685
[TBL] [Abstract][Full Text] [Related]
48. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.
Staller P; Sulitkova J; Lisztwan J; Moch H; Oakeley EJ; Krek W
Nature; 2003 Sep; 425(6955):307-11. PubMed ID: 13679920
[TBL] [Abstract][Full Text] [Related]
49. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.
Ivanov SV; Kuzmin I; Wei MH; Pack S; Geil L; Johnson BE; Stanbridge EJ; Lerman MI
Proc Natl Acad Sci U S A; 1998 Oct; 95(21):12596-601. PubMed ID: 9770531
[TBL] [Abstract][Full Text] [Related]
50. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
[TBL] [Abstract][Full Text] [Related]
51. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
52. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
[TBL] [Abstract][Full Text] [Related]
53. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
Datta K; Sundberg C; Karumanchi SA; Mukhopadhyay D
Cancer Res; 2001 Mar; 61(5):1768-75. PubMed ID: 11280720
[TBL] [Abstract][Full Text] [Related]
54. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
55. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
[TBL] [Abstract][Full Text] [Related]
56. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
[TBL] [Abstract][Full Text] [Related]
57. Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells.
Alberghini A; Recalcati S; Tacchini L; Santambrogio P; Campanella A; Cairo G
J Biol Chem; 2005 Aug; 280(34):30120-8. PubMed ID: 15985433
[TBL] [Abstract][Full Text] [Related]
58. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
59. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.
Bluyssen HA; Lolkema MP; van Beest M; Boone M; Snijckers CM; Los M; Gebbink MF; Braam B; Holstege FC; Giles RH; Voest EE
FEBS Lett; 2004 Jan; 556(1-3):137-42. PubMed ID: 14706840
[TBL] [Abstract][Full Text] [Related]
60. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility.
Kamada M; Suzuki K; Kato Y; Okuda H; Shuin T
Cancer Res; 2001 May; 61(10):4184-9. PubMed ID: 11358843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
